After the 2005 milestone in clinical application of paclitaxel¿albumin nanoparticles (NPs) for the treatment of metastatic breast cancer,[1] albumin NPs have been thoroughly investigated as effective delivery systems in nanomedicine.[2] This has led to increasing interest in the use of bovine serum albumin (BSA) as nanocarrier for applications in nanomedicine,[3a¿c] due to the possibility to coat lipophilicNPsand because it can be considered a crucial step before moving to its human version, human serum albumin (HSA).[3d¿f] The scientific community is seeking to exploit the intrinsic properties of magnetic nanoparticles (MNPs) to obtain medical breakthroughs in diagnosis and therapy.
COMES FRANCHINI Mauro;
BALDI Giovanni;
BONACCHI Daniele;
GENTILE Denis;
GIUDETTI Guido;
LASCIALFARI Alessandro;
CORTI Maurizio;
MARMORATO Patrick;
PONTI Jessica;
MICOTTI Edoardo;
GUERRINI Uliano;
SIRONI Luigi;
GELOSA Paolo;
RAVAGLI Costanza;
RICCI Alfredo;
2010-02-08
WILEY-V C H VERLAG GMBH
JRC54998
1613-6810,
https://publications.jrc.ec.europa.eu/repository/handle/JRC54998,
10.1002/smll.200901689,
| Name | Country | City | Type |
|---|
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Datasets
| ID | Title | Public URL |
|---|
Dataset collections
| ID | Acronym | Title | Public URL |
|---|
Scripts / source codes
| Description | Public URL |
|---|
Additional supporting files
| File name | Description | File type |
|---|